Delcath ended the quarter with $95.9 million in cash and investments and generated $5.7 million in operating cash flow. Delcath increased its full-year 2026 revenue guidance to a range of $104 million to $108 million. Michel said a meaningful percentage of company volume is now covered by centers with backup teams, including some higher-volume sites. In HER2-negative metastatic breast cancer, Delcath recently dosed its first patient at the European Institute of Oncology in Milan. Delcath is also preparing for pre-IND meetings with the Food and Drug Administration later this year to discuss potential additional indications, Michel said.